US regulators have withdrawn their approval of a GSK Plc drug that the Trump administration had promoted as a treatment for autism, adding another twist to the unusual story of a decades-old drug.
The FDA has issued a warning letter to Medline over manufacturing and quality control failures in its angiographic syringe kits, citing risks such as air embolism and contamination. Separately, GSK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results